Immunicon Corp.

There’s no doubt biomarker diagnostics are the linchpin of personalized medicine. But building a successful business around such tests is anything but straightforward, given the complexities associate

Johnson & Johnson isn't the ground shaker in molecular testing that Roche Diagnostics is—so it is forging a different path to becoming a leader in emerging high-potential sectors of the in vitro

In recent years, there has been virtually no IPO activity in the medical device arena; the only viable exit option for private investors was trade sale. Yet while M&A activity remains strong, 2004 has

After years of confusion and stagnation, the field of cancer biomarker diagnostics seems to be progressing, even as huge challenges remain. Investors are alert but cautious. After years of false hope